pLX303-ZIM3-KRAB-dCas9 Citations (5)
Originally described in: An efficient KRAB domain for CRISPRi applications in human cells.Alerasool N, Segal D, Lee H, Taipale M Nat Methods. 2020 Nov;17(11):1093-1096. doi: 10.1038/s41592-020-0966-x. Epub 2020 Oct 5. PubMed Journal
Articles Citing pLX303-ZIM3-KRAB-dCas9
| Articles |
|---|
| DNA methylation-independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins. Ding L, Schmitt LT, Brux M, Surun D, Augsburg M, Lansing F, Mircetic J, Theis M, Buchholz F. Life Sci Alliance. 2022 Mar 14;5(6). pii: 5/6/e202101321. doi: 10.26508/lsa.202101321. Print 2022 Jun. PubMed |
| Histone methyltransferase Dot1L recruits O-GlcNAc transferase to target chromatin sites to regulate histone O-GlcNAcylation. Xu B, Zhang C, Jiang A, Zhang X, Liang F, Wang X, Li D, Liu C, Liu X, Xia J, Li Y, Wang Y, Yang Z, Chen J, Zhou Y, Chen L, Sun H. J Biol Chem. 2022 Jul;298(7):102115. doi: 10.1016/j.jbc.2022.102115. Epub 2022 Jun 9. PubMed |
| Virtual cells in a virtual microenvironment recapitulate early development-like patterns in human pluripotent stem cell colonies. Kaul H, Werschler N, Jones RD, Siu MM, Tewary M, Hagner A, Ostblom J, Aguilar-Hidalgo D, Zandstra PW. Stem Cell Reports. 2023 Jan 10;18(1):377-393. doi: 10.1016/j.stemcr.2022.10.004. Epub 2022 Nov 3. PubMed |
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.
Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, Russell BJ, Wang X, Leng K, Guna A, Norman TM, Pak RA, Ramos DM, Ward ME, Gilbert LA, Kampmann M, Weissman JS, Jost M.
Elife. 2022 Dec 28;11:e81856. doi: 10.7554/eLife.81856.
PubMed
Associated Plasmids |
| Retrotransposons hijack alt-EJ for DNA replication and eccDNA biogenesis. Yang F, Su W, Chung OW, Tracy L, Wang L, Ramsden DA, Zhang ZZZ. Nature. 2023 Aug;620(7972):218-225. doi: 10.1038/s41586-023-06327-7. Epub 2023 Jul 12. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.